Chronic berylliosis;Chronische berylliose

Pneumologie

Volumn 61, Issue 2, 2007, Pages 109-116

  Muller Quernheim J ^a   Gaede, K I ^b   Prasse, A ^a   Zissel, G ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM; CORTICOSTEROID; PREDNISONE;

BERYLLIOSIS; CHRONIC DISEASE; CLINICAL FEATURE; DIAGNOSTIC TEST; GERMANY; GRANULOMATOSIS; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; LUNG TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; OCCUPATIONAL DISEASE; OCCUPATIONAL HAZARD; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS;

BERYLLIOSIS; BERYLLIUM; DIAGNOSIS, DIFFERENTIAL; GERMANY; HUMANS; SARCOIDOSIS;

EID: 34047110358     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-954984     Document Type: Review

References (90)

1. Jones Williams W. Beryllium disease. In: James D (ed). Sarcoidosis and other granulomatous disorders. New York: Marcel Dekker, 1994: 707-721
2. Meyer K. Beryllium and lung disease disease. Chest 1994; 106: 942-946
3. Schonherr S, Pevny H. Berylliumallergie. Arbeitsmed Sozialmed Präventivmed 1985; 20: 281-286
4. Rietschel R, Vowler JJ. Fisher's contact dermatitis. 4th ed. Baltimore: Williams & Wilkens, 1995
5. MacMahon B. The epidemiological evidence on the carcinogenicity of Beryllium in humans. J Occup Med 1994; 36: 15-24
6. Steenland K, Ward E. Lung cancer incidence among patients with Beryllium disease: A cohort mortality study. J Nat Cancer Inst 1991; 83: 1380-1385
7. Askling J, Grunewald J, Eklund A et al. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999; 160: 1668-1672
8. Sanderson WT, Petersen MR, Ward EM. Estimating historical exposures of workers in a beryllium manufacturing plant. Am J Ind Med 2001; 39: 145-157
9. Sanderson WT, Ward EM, Steenland K et al. Lung cancer case-control study of beryllium workers. Am J Ind Med 2001; 39: 133-144
10. Senatskommisssion zur Prüfung gesundheitsschädlicher Arbeitsstoffe der Deutschen Forschungsgemeinschaft. Beryllium und seine anorganischen Verbindungen. In: Greim H (ed). Gesundheitsschädliche Arbeitsstoffe Toxikologisch-arbeitsmedizinische Begründungen von MAK-Werten (Maximale Arbeitsplatzkonzentrationen). Weinheim: VCH Verlagsgesellschaft, 2003: 37. Lieferung
11. Newman LS. Metals that cause sarcoidosis. Semin Respir Infect 1998; 13: 212-220
12. Newman LS. Beryllium disease and sarcoidosis: Clinical and laboratory links. Sarcoidosis 1995; 12: 7-19
13. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: Identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992; 145: 1212-1214
14. Middleton DC. Chronic beryllium disease: uncommon disease, less common diagnosis. Environ Health Perspect 1998; 106: 765-767
15. Rossman MD. Chronic beryllium disease: diagnosis and management. Environ Health Perspect 1996; 104 Suppl 5: 945-947
16. Müller-Quernheim J, Gaede KI, Fireman E et al. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006; 27: 1190-1195
17. Infante PF, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004; 363: 415-416
18. Henneberger PK, Goe SK, Miller WE et al. Prevention of beryllium sensitization and chronic beryllium disease. J Occup Environ Hyg 2006; 3: D42-43
19. Rossman MD, Kreider ME. Is chronic beryllium disease sarcoidosis of known etiology? Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 104-109
20. 3. Am J Ind Med 1996; 30: 16-25
21. Hooper WF. Acute beryllium lung disease. N C Med J 1981; 42: 551-553
22. Kriebel D, Sprince NL, Eisen EA et al. Pulmonary function in beryllium workers: assessment of exposure. Br J Ind Med 1988; 45: 83-92
23. Drexler H, Greim H. The MAK-Collection Part II: BAT Value Documentations, Volume 4. Weinheim: Wiley-VCH, 2005
24. Willis HH, Florig HK. Potential exposures and risks from beryllium-containing products. Risk Anal 2002; 22: 1019-1033
25. Maier L, Martyny J, Mroz M et al. Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease. Chest 2002; 121: 81S
26. Henneberger PK, Cumro D, Deubner DD et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001; 74: 167-176
27. Kreiss K, Wassermann S, Mroz MM et al. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993; 35: 267-274
28. Newman LS, Mroz MM, Balkissoon R et al. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171: 54-60
29. Newman LS, Mroz MM, Maier LA et al. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 2001; 43: 231-237
30. Entzian P, Pawelek W, Lindner B et al. Grenzen des Berylliumnachweises mit der Laser-Mikrobereichs-Massenspektrometrie [Limits of beryllium detection with laser microprobe mass spectrometry (LAMMS)]. Pneumologie 1998; 52: 674-679
31. Sumino K, Hayakawa K, Shibata T et al. Heavy metals in normal Japanese tissues. Amounts of 15 heavy metals in 30 subjects. Arch Environ Health 1975; 30: 487-494
32. Wegner R, Heinrich-Ramm R, Nowak D et al. Lung function, biological monitoring, and biological effect monitoring of gemstone cutters exposed to beryls. Occup Environ Med 2000; 57: 133-139
33. Verma DK, Ritchie AC, Shaw ML. Measurement of beryllium in lung tissue of a chronic beryllium disease case and cases with sarcoidosis. Occup Med (Lond) 2003; 53: 223-227
34. Cullen MR, Kominsky JR, Rossman MD et al. Chronic beryllium disease in a precious metal refinery. Clinical epidemiologic and immunologic evidence for continuing risk from exposure to low level beryllium fume. Am Rev Respir Dis 1987; 135: 201-208
35. Bartell SM, Ponce RA, Takaro TK et al. Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention. Risk Anal 2000; 20: 87-99
36. Müller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12: 716-738
37. Bost TW, Riches DWH, Schumacher B et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6 but not interleukin-1β. Am J Respir Cell Mol Biol 1994; 10: 506-513
38. Gaede KI, Mamat U, Schlaak M et al. Analysis of differentially regulated mRNAs in peripheral blood monocytes of berylliosis patients after in vitro stimulation. J Mol Med 2000; 78: 293-299
39. Richeldi L, Sorrentino R, Saltini C. HLA-DPB 1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262: 242-244
40. Richeldi L, Kreiss K, Mroz MM et al. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997; 32: 337-340
41. Wang Z, White PS, Petrovic M et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999; 163: 1647-1653
42. Rossman MD, Stubbs J, Lee CW et al. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002; 165: 788-794
43. Saltini C, Richeldi L, Losi M et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001; 18: 677-684
44. Maier LA, Sawyer RT, Bauer RA et al. High beryllium-stimulated TNF-α is associated with the -308 TNF-α promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med 2001; 164: 1192-1199
45. Gaede KI, Amicosante M, Schurmann M et al. Function associated transforming growth factor-β gene polymorphism in chronic beryllium disease. J Mol Med 2005; 83: 397-405
46. Maier LA, Raynolds MV, Young DA et al. Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am J Respir Crit Care Med 1999; 159: 1342-1350
47. Newman LS, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis 1992; 146: 39-42
48. Weston A, Ensey J, Kreiss K et al. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease. Am J Ind Med 2002; 41: 457-465
49. Maier LA. Genetic and exposure risks for chronic beryllium disease. Clin Chest Med 2002; 23: 827-839
50. Saltini C, Amicosante M, Franchi A et al. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Eur Respir J 1998; 12: 1463-1475
51. McCunney RJ. Genetic testing: ethical implications in the workplace. Occup Med 2002; 17: 665-672
52. Amicosante M, Sanarico N, Berretta F et al. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Hum Immunol 2001; 62: 686-693
53. Lombardi G, Germain C, Uren J et al. HLA-DP allele-specific T cell responses to beryllium account for DP- associated susceptibility to chronic beryllium disease. J Immunol 2001; 166: 3549-3555
54. Fontenot AP, Torres M, Marshall WH et al. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000; 97: 12 717-12 722
55. Saltini C, Winestock K, Kirby M et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989; 320: 1103-1109
56. Saltini C, Kirby M, Trapnell BC et al. Biased accumulation of T lymphocytes with "memory"-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med 1990; 171: 1123-1140
57. Fontenot AP, Canavera SJ, Gharavi L et al. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest 2002; 110: 1473-1482
58. Fontenot AP, Falta MT, Freed BM et al. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999; 163: 1019-1026
59. Amicosante M, Berretta F, Franchi A et al. HLA-DP-unrestricted TNF-α release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J 2002; 20: 1174-1178
60. Tinkle SS, Schwitters PW, Newman LS. Cytokine production by bronchoalveolar lavage cells in chronic beryllium disease. Environ Health Perspect 1996; 104 Suppl 5: 969-971
61. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003; 253: 18-30
62. Middleton DC, Lewin MD, Kowalski PJ et al. The BeLPT: algorithms and implications. Am J Ind Med 2006; 49: 36-44
63. Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance. Am J Ind Med 2004; 46: 453-462
64. Taylor TP, Ding M, Ehler DS et al. Beryllium in the environment: a review. J Environ Sci Health A Tox Hazard Subst Environ Eng 2003; 38: 439-469
65. Vilaplana J, Romaguera C, Grimalt F. Occupational and non-occupational allergic contact dermatitis from beryllium. Contact Dermatitis 1992; 26: 295-298
66. Bobka CA, Stewart LA, Engelken GJ et al. Comparison of in vivo and in vitro measures of beryllium sensitization. J Occup Environ Med 1997; 39: 540-547
67. Schreiber J, Zissel G, Greinert U et al. Diagnostik der chronischen Berylliosis. Pneumologie 1999; 53: 193-198
68. Curtis G. The diagnosis of Beryllium disease, with special reference to the patch test. Arch Indust Health 1959; 19: 150-153
69. Newman LS, Kreiss K, King TE et al. Pathological and immunological alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989; 139: 1479-1486
70. Lundgren RA, Maier LA, Rose CS et al. Indirect and direct gas exchange at maximum exercise in beryllium sensitization and disease. Chest 2001; 120: 1702-1708
71. Daniloff EM, Lynch DA, Bartelson BB et al. Observer variation and relationship of computed tomography to severity of beryllium disease. Am J Respir Crit Care Med 1997; 155: 2047-2056
72. Newman LS, Buschman DL, Newell JD Jr et al. Beryllium disease: assessment with CT. Radiology 1994; 190: 835-840
73. Stange AW, Furman FJ, Hilmas DE. Rocky Flats Beryllium Health Surveillance. Environ Health Perspect 1996; 104S: 981-986
74. Kreiss K, Mroz MM, Zhen B et al. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997; 54: 605-612
75. Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in Beryllium disease. Am Rev Respir Dis 1993; 148: 661-666
76. Kreiss K, Mroz MM, Zhen B et al. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993; 148: 985-991
77. Schepers G. The mineral content of the lung in chronic berylliosis. J Dis Chest 1962; 42: 600-607
78. Kent DC, Houk VN, Elliott RC et al. The definitive evaluation of sarcoidosis. Am Rev Respir Dis 1970; 101: 721-727
79. Grunewald J, Eklund A. [It's difficult to differentiate between sarcoidosis and berylliosis!]. Lakartidningen 2000; 97: 5915-5918
80. Fireman E, Kramer MR, Kaufman N et al. Beryllium disease: first case reported in Israel. Isr Med Assoc J 2001; 3: 224-225
81. Bargon J, Rust M, Kronenberger H et al. Klinik und Diagnostik der chronischen Berylliose - Eine Kasuistik. Pneumologie 1990; 44 Suppl 1: 320-321
82. Müller-Quernheim J, Zissel G, Schopf R et al. Differenzialdiagnose Berylliose/Sarkoidose bei einem Zahntechniker. Dtsch Med Wochenschr 1996; 121: 1462-1466
83. Sprince NL, Kanarek DJ, Weber AL et al. Reversible respiratory disease in beryllium workers. Am Rev Respir Dis 1978; 117: 1011-1017
84. Müller-Quernheim J. Die Indikation zur Kortikosteroid- Therapie der Sarkoidose und die Bewertung ihrer Resultate. Pneumologie 2000; 54: 284-286
85. Müller-Quernheim J. Sarcoidosis, part II: Clinical manifestations, staging, and therapy. Respir Med 1998; 92: 140-139
86. Müller-Quernheim J, Dalhoff K, Schnabel A. Immunsuppressive Therapie bei interstitiellen Lungenerkrankungen und immunologisch vermittelten Pneumonitiden. Internist (Berl) 1997; 38: 553-561
87. Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 2004; 126: 2000-2007
88. Nagaoka K, Yoshida T, Sakakibara H et al. Significant improvement from chronic beryllium disease following corticosteroid pulse therapy. Ind Health 2006; 44: 296-301
89. Müller-Quernheim J, Kienast K, Held M et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122
90. Lang L. Beryllium: A Chronic Problem. Environ Health Perspect 1994; 102: 526-531